Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Down 36.3% in May

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a large decrease in short interest in the month of May. As of May 31st, there was short interest totalling 5,800 shares, a decrease of 36.3% from the May 15th total of 9,100 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 23,500 shares, the short-interest ratio is currently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. BlueCrest Capital Management Ltd purchased a new position in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 542,673 shares of the company’s stock, valued at approximately $1,292,000. BlueCrest Capital Management Ltd owned about 1.39% of Barinthus Biotherapeutics as of its most recent filing with the SEC. Institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Stock Down 4.2 %

Shares of NASDAQ BRNS traded down $0.08 during midday trading on Friday, reaching $1.83. 7,672 shares of the company were exchanged, compared to its average volume of 17,342. The stock’s 50-day moving average price is $2.35 and its 200-day moving average price is $2.73. The stock has a market cap of $71.42 million, a P/E ratio of -0.99 and a beta of -0.46. Barinthus Biotherapeutics has a one year low of $1.64 and a one year high of $5.10.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.24. On average, equities research analysts anticipate that Barinthus Biotherapeutics will post -2.3 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on BRNS shares. Barclays lowered their price objective on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an “overweight” rating for the company in a research report on Thursday. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Barinthus Biotherapeutics in a research report on Friday, June 7th. Finally, William Blair reiterated an “outperform” rating on shares of Barinthus Biotherapeutics in a research report on Thursday.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.